Complement decay-accelerating factor (CD55) has been identified by immunohistochemistry in pancreatic cancer, and its elevated levels correlate positively with tumour aggressiveness, vascular invasion, and prognosis [32]. Here, CD55 is linked to familial pancreatic carcinoma.